Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 May 28;14(1):84.
doi: 10.1186/s13045-021-01094-2.

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Jaime Sanz  1   2 , Jacques-Emmanuel Galimard  3 , Myriam Labopin  3 , Boris Afanasyev  4 , Moiseev Ivan Sergeevich  4 , Emanuele Angelucci  5 , Nicolaus Kröger  6 , Yener Koc  7 , Fabio Ciceri  8 , J L Diez-Martin  9 , Mutlu Arat  10 , Simona Sica  11 , Montserrat Rovira  12   13 , Mahmoud Aljurf  14 , Johanna Tischer  15 , Bipin Savani  16 , Annalisa Ruggeri  8 , Arnon Nagler  17 , Mohamad Mohty  18
Affiliations
Comparative Study

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Jaime Sanz et al. J Hematol Oncol. .

Abstract

Background: There is no information on the impact of donor type in allogeneic hematopoietic stem cell transplantation (HCT) using homogeneous graft-versus-host (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) in acute lymphoblastic leukemia (ALL).

Methods: We retrospectively analyzed outcomes of adult patients with ALL in CR1 that had received HCT with PTCy as GVHD prophylaxis from HLA-matched sibling (MSD) (n = 78), matched unrelated (MUD) (n = 94) and haploidentical family (Haplo) (n = 297) donors registered in the EBMT database between 2010 and 2018. The median follow-up period of the entire cohort was 2.2 years.

Results: Median age of patients was 38 years (range 18-76). Compared to MSD and MUD, Haplo patients received peripheral blood less frequently. For Haplo, MUD, and MSD, the cumulative incidence of 100-day acute GVHD grade II-IV and III-IV, and 2-year chronic and extensive chronic GVHD were 32%, 41%, and 34% (p = 0.4); 13%, 15%, and 15% (p = 0.8); 35%, 50%, and 42% (p = 0.01); and 11%, 17%, and 21% (p = 0.2), respectively. At 2 years, the cumulative incidence of relapse and non-relapse mortality was 20%, 20%, and 28% (p = 0.8); and 21%, 18%, and 21% (p = 0.8) for Haplo, MUD, and MSD, respectively. The leukemia-free survival, overall survival and GVHD-free, relapse-free survival for Haplo, MUD, and MSD was 59%, 62%, and 51% (p = 0.8); 66%, 69%, and 62% (p = 0.8); and 46%, 44%, and 35% (p = 0.9), respectively. On multivariable analysis, transplant outcomes did not differ significantly between donor types. TBI-based conditioning was associated with better LFS.

Conclusions: Donor type did not significantly affect transplant outcome in patient with ALL receiving SCT with PTCy.

Trial registration: ClinicalTrials.gov NCT04232241.

Keywords: Acute lymphoblastic leukemia; Allogeneic stem cell transplant; Alternative donor transplants; Haploidentical transplant; Post-transplant cyclophosphamide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Cumulative incidence of relapse according to donor type
Fig. 2
Fig. 2
Cumulative incidence of non-relapse mortality according to donor type
Fig. 3
Fig. 3
Probability of leukemia-free survival according to donor type
Fig. 4
Fig. 4
Probability of overall survival according to donor type
See this image and copyright information in PMC

References

    1. DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2113–2123. doi: 10.1016/j.bbmt.2019.08.014. - DOI - PubMed
    1. Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant. 2019;54:798–809. doi: 10.1038/s41409-018-0373-4. - DOI - PubMed
    1. Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891–1900. doi: 10.1038/leu.2015.98. - DOI - PubMed
    1. Malki Al MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, et al. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv. 2020;4:2073–2083. doi: 10.1182/bloodadvances.2020001499. - DOI - PMC - PubMed
    1. Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, et al. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia. 2020;34:283–292. doi: 10.1038/s41375-019-0544-3. - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data